NASDAQ:APHA

Aphria Competitors

$14.14
+0.55 (+4.05 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.32
Now: $14.14
$14.18
50-Day Range
$13.59
MA: $17.73
$22.17
52-Week Range
$2.78
Now: $14.14
$32.29
Volume10.04 million shs
Average Volume23.59 million shs
Market Capitalization$4.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.67

Competitors

Aphria (NASDAQ:APHA) Vs. CGC, CRON, TLRY, USNA, ACB, and SNDL

Should you be buying APHA stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Aphria, including Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), Aurora Cannabis (ACB), and Sundial Growers (SNDL).

Canopy Growth (NASDAQ:CGC) and Aphria (NASDAQ:APHA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Canopy Growth and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Aphria-36.10%-2.30%-1.66%

Insider and Institutional Ownership

10.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. 0.3% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Canopy Growth has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500.

Valuation and Earnings

This table compares Canopy Growth and Aphria's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million35.73$-993,370,000.00$1.3221.06
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67

Aphria has higher revenue and earnings than Canopy Growth. Aphria is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Canopy Growth and Aphria, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth510211.94
Aphria05302.38

Canopy Growth presently has a consensus price target of $35.6778, indicating a potential upside of 28.34%. Aphria has a consensus price target of $22.00, indicating a potential upside of 55.59%. Given Aphria's stronger consensus rating and higher possible upside, analysts plainly believe Aphria is more favorable than Canopy Growth.

Summary

Aphria beats Canopy Growth on 10 of the 15 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Aphria (NASDAQ:APHA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cronos Group and Aphria, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24101.86
Aphria05302.38

Cronos Group presently has a consensus price target of $8.75, indicating a potential upside of 4.67%. Aphria has a consensus price target of $22.00, indicating a potential upside of 55.59%. Given Aphria's stronger consensus rating and higher possible upside, analysts plainly believe Aphria is more favorable than Cronos Group.

Profitability

This table compares Cronos Group and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Aphria-36.10%-2.30%-1.66%

Volatility & Risk

Cronos Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500.

Insider and Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cronos Group and Aphria's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million117.46$1.17 billion$0.6712.48
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67

Cronos Group has higher earnings, but lower revenue than Aphria. Aphria is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Aphria on 9 of the 14 factors compared between the two stocks.

Aphria (NASDAQ:APHA) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Aphria and Tilray, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria05302.38
Tilray19001.90

Aphria currently has a consensus target price of $22.00, indicating a potential upside of 55.59%. Tilray has a consensus target price of $18.3078, indicating a potential upside of 6.44%. Given Aphria's stronger consensus rating and higher possible upside, research analysts clearly believe Aphria is more favorable than Tilray.

Profitability

This table compares Aphria and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
Tilray-242.60%-92.70%-20.70%

Risk and Volatility

Aphria has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, meaning that its stock price is 212% more volatile than the S&P 500.

Insider & Institutional Ownership

10.3% of Aphria shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Aphria and Tilray's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67
Tilray$166.98 million17.69$-321,170,000.00($1.69)-10.18

Aphria has higher revenue and earnings than Tilray. Aphria is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks.

Summary

Aphria beats Tilray on 9 of the 14 factors compared between the two stocks.

Aphria (NASDAQ:APHA) and USANA Health Sciences (NYSE:USNA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility and Risk

Aphria has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Aphria and USANA Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
USANA Health Sciences10.57%32.91%22.26%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aphria and USANA Health Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria05302.38
USANA Health Sciences00203.00

Aphria currently has a consensus target price of $22.00, indicating a potential upside of 55.59%. USANA Health Sciences has a consensus target price of $126.00, indicating a potential upside of 27.41%. Given Aphria's higher possible upside, analysts plainly believe Aphria is more favorable than USANA Health Sciences.

Valuation and Earnings

This table compares Aphria and USANA Health Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42

USANA Health Sciences has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

10.3% of Aphria shares are held by institutional investors. Comparatively, 54.1% of USANA Health Sciences shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

USANA Health Sciences beats Aphria on 10 of the 14 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Aphria (NASDAQ:APHA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Aurora Cannabis and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Aphria-36.10%-2.30%-1.66%

Risk and Volatility

Aurora Cannabis has a beta of 3.44, indicating that its stock price is 244% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500.

Valuation and Earnings

This table compares Aurora Cannabis and Aphria's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67

Aphria has higher revenue and earnings than Aurora Cannabis. Aphria is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Aurora Cannabis and Aphria, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
Aphria05302.38

Aurora Cannabis presently has a consensus price target of $10.9264, indicating a potential upside of 38.66%. Aphria has a consensus price target of $22.00, indicating a potential upside of 55.59%. Given Aphria's stronger consensus rating and higher possible upside, analysts clearly believe Aphria is more favorable than Aurora Cannabis.

Summary

Aphria beats Aurora Cannabis on 10 of the 13 factors compared between the two stocks.

Aphria (NASDAQ:APHA) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Aphria and Sundial Growers' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67
Sundial Growers$75.86 million18.54$-204,570,000.00($3.17)-0.27

Aphria has higher revenue and earnings than Sundial Growers. Aphria is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aphria and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
Sundial Growers-415.89%-187.67%-72.67%

Volatility & Risk

Aphria has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, meaning that its share price is 601% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Aphria and Sundial Growers, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria05302.38
Sundial Growers32001.40

Aphria presently has a consensus target price of $22.00, indicating a potential upside of 55.59%. Sundial Growers has a consensus target price of $0.7333, indicating a potential downside of 13.42%. Given Aphria's stronger consensus rating and higher probable upside, research analysts clearly believe Aphria is more favorable than Sundial Growers.

Insider & Institutional Ownership

10.3% of Aphria shares are owned by institutional investors. Comparatively, 3.3% of Sundial Growers shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aphria beats Sundial Growers on 10 of the 13 factors compared between the two stocks.


Aphria Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
1.0$27.80+1.4%$10.62 billion$297.34 million-8.32News Coverage
Cronos Group logo
CRON
Cronos Group
0.8$8.36+2.6%$3.01 billion$25.64 million34.83Analyst Downgrade
Tilray logo
TLRY
Tilray
1.0$17.20+1.5%$2.95 billion$166.98 million-3.79News Coverage
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89+2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88+1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85+1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
HEXO logo
HEXO
HEXO
1.1$5.52+3.3%$676.12 million$60.46 million-1.13Gap Up
ChromaDex logo
CDXC
ChromaDex
1.3$8.20+4.0%$547.41 million$46.29 million-21.58
MediWound logo
MDWD
MediWound
1.4$5.04+2.0%$137.27 million$31.79 million-12.60Decrease in Short Interest
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$18.20+6.3%$115.72 million$118.88 million227.53High Trading Volume
Increase in Short Interest
Gap Up
HAPP
Happiness Biotech Group
0.6$1.84+0.5%$47.53 million$65.06 million0.00Increase in Short Interest
News Coverage
Mannatech logo
MTEX
Mannatech
1.3$19.13+2.4%$39.58 million$157.73 million5.89Gap Down
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.56+1.9%$29.89 million$190,000.00-0.35Increase in Short Interest
News Coverage
CYAN
Cyanotech
0.6$3.14+1.6%$19.15 million$31.90 million31.40
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.